The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for ivWatch sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
ivWatch is a medical device company that manufactures and markets IV infiltration detection technology with patient monitoring systems that detects infiltration extravasation events. It offers ivWatch Model 400, a device used to help clinicians monitor the status of a patient’s IV to aid in the early detection of peripheral IV infiltrations and extravasations. Through the use of non-invasive sensor technology, the ivWatch Model 400 can help reduce potentially serious medication dosing errors and associated patient harm from infiltration events. The company is transforming IV therapy by improving patient care and safety and provides healthcare providers with cost-effective solutions for continuously monitoring peripheral IVs. ivWatch is headquartered in Newport News, Virginia, the US.
The key metrics of ivWatch related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As ivWatch is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as ivWatch.
For a detailed understanding of the performance of ivWatch, buy the report here.